Press Releases 2025 2024 2023 2022 2021 2020 2019 all November 3, 2022 Dyne Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights November 2, 2022 Dyne Therapeutics to Present at Investor Conferences in November October 31, 2022 Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy October 11, 2022 Dyne Therapeutics Presents Preclinical Data from its Duchenne Muscular Dystrophy Programs Targeting Exons 51 and 53 at World Muscle Society 2022 Congress September 27, 2022 Dyne Therapeutics to Present at Chardan’s 6th Annual Genetic Medicines Conference September 12, 2022 Dyne Therapeutics Highlights DM1 and DMD Clinical Programs During “Spotlight on the Clinic” Virtual Event September 6, 2022 Dyne Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference September 6, 2022 Dyne Therapeutics Announces Initiation of Phase 1/2 ACHIEVE Clinical Trial of DYNE-101 for the Treatment of Myotonic Dystrophy Type 1 September 6, 2022 Dyne Therapeutics Announces First Patient Dosed in Phase 1/2 DELIVER Clinical Trial of DYNE-251 for the Treatment of Duchenne Muscular Dystrophy August 29, 2022 Dyne Therapeutics Appoints Francesco Bibbiani, M.D., as Senior Vice President, Head of Development August 10, 2022 Dyne Therapeutics Announces “Breakthrough Article” Publication of Duchenne Muscular Dystrophy Program Data in Nucleic Acids Research August 4, 2022 Dyne Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights July 12, 2022 Dyne Therapeutics Announces Clearance of Clinical Trial Application for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1 July 5, 2022 Dyne Therapeutics Announces FDA Clearance of IND Application for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy June 3, 2022 Dyne Therapeutics to Present at Jefferies Global Healthcare Conference May 16, 2022 Dyne Therapeutics Presents New In Vivo Data from DYNE-101 at ASGCT Annual Meeting Demonstrating Low Monthly Dosing Leads to Robust DMPK RNA Knockdown May 2, 2022 Dyne Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights March 10, 2022 Dyne Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights March 3, 2022 Dyne Therapeutics Appoints Carlo Incerti, M.D., to its Board of Directors January 18, 2022 Dyne Therapeutics Announces FDA Clinical Hold on IND Application for DYNE-251 in Duchenne Muscular Dystrophy Pagination Current page 1 Page 2 Next page › Last page » Displaying 1 - 20 of 21
